Stock Track | Abbott Laboratories Soars 5.07% in Pre-market on Strong Q2 Earnings and Raised 2026 Forecast

Stock Track

Jul 16

Abbott Laboratories' stock surged 5.07% in pre-market trading following the release of its second-quarter financial results.

The healthcare company reported adjusted earnings per share of $1.31 for the quarter, beating the consensus estimate of $1.28. Revenue came in at $12.59 billion, also exceeding expectations of $12.52 billion. Additionally, Abbott raised its full-year 2026 adjusted EPS guidance to a range of $5.45 to $5.60, up from its previous forecast of $5.38 to $5.58 and above analyst estimates.

The strong performance was driven by robust growth in the company's diagnostics and medical devices segments. The diagnostics business saw significant expansion, particularly in cancer diagnostics following the acquisition of Exact Sciences, while heart devices and diabetes care products also showed strong demand that is expected to continue through the second half of the year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1156047545"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1156047545\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1156047545?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-16 21:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156047545","market":"nz","top_or_hot":-1,"title":"Stock Track | Abbott Laboratories Soars 5.07% in Pre-market on Strong Q2 Earnings and Raised 2026 Forecast","media":"Stock Track","content":"<p>Abbott Laboratories' stock surged 5.07% in pre-market trading following the release of its second-quarter financial results.</p><p>The healthcare company reported adjusted earnings per share of $1.31 for the quarter, beating the consensus estimate of $1.28. Revenue came in at $12.59 billion, also exceeding expectations of $12.52 billion. Additionally, Abbott raised its full-year 2026 adjusted EPS guidance to a range of $5.45 to $5.60, up from its previous forecast of $5.38 to $5.58 and above analyst estimates.</p><p>The strong performance was driven by robust growth in the company's diagnostics and medical devices segments. The diagnostics business saw significant expansion, particularly in cancer diagnostics following the acquisition of Exact Sciences, while heart devices and diabetes care products also showed strong demand that is expected to continue through the second half of the year.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Abbott Laboratories Soars 5.07% in Pre-market on Strong Q2 Earnings and Raised 2026 Forecast</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Abbott Laboratories Soars 5.07% in Pre-market on Strong Q2 Earnings and Raised 2026 Forecast\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-07-16 21:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Abbott Laboratories' stock surged 5.07% in pre-market trading following the release of its second-quarter financial results.</p><p>The healthcare company reported adjusted earnings per share of $1.31 for the quarter, beating the consensus estimate of $1.28. Revenue came in at $12.59 billion, also exceeding expectations of $12.52 billion. Additionally, Abbott raised its full-year 2026 adjusted EPS guidance to a range of $5.45 to $5.60, up from its previous forecast of $5.38 to $5.58 and above analyst estimates.</p><p>The strong performance was driven by robust growth in the company's diagnostics and medical devices segments. The diagnostics business saw significant expansion, particularly in cancer diagnostics following the acquisition of Exact Sciences, while heart devices and diabetes care products also showed strong demand that is expected to continue through the second half of the year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABT","symbol_name":"雅培","start_time":0,"source_url":"","article_id":"1156047545","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156047545","pubTimestamp":1784207906,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Abbott Laboratories' stock surged 5.07% in pre-market trading following the release of its second-quarter financial results.The healthcare company reported adjusted earnings per share of $1.31 for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABT":"雅培"},"translate_title":"股票跟踪 | 雅培实验室第二季度盈利强劲并上调 2026 年预测，盘前股价飙升 5.07%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABT":1},"content_text":"Abbott Laboratories' stock surged 5.07% in pre-market trading following the release of its second-quarter financial results.The healthcare company reported adjusted earnings per share of $1.31 for the quarter, beating the consensus estimate of $1.28. Revenue came in at $12.59 billion, also exceeding expectations of $12.52 billion. Additionally, Abbott raised its full-year 2026 adjusted EPS guidance to a range of $5.45 to $5.60, up from its previous forecast of $5.38 to $5.58 and above analyst estimates.The strong performance was driven by robust growth in the company's diagnostics and medical devices segments. The diagnostics business saw significant expansion, particularly in cancer diagnostics following the acquisition of Exact Sciences, while heart devices and diabetes care products also showed strong demand that is expected to continue through the second half of the year.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}